Clinical trial
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
NCT00089076 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00089076 |
|---|---|
| Title | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma |
| Official title | Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and 13 more |
| Intervention type | Biological, Other |
| Interventions | ipilimumab, laboratory biomarker analysis |
| Enrollment | 18 |
| Start date | Jun 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Aug 5, 2004 |
| Last update posted | May 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: